Relay Therapeutics Inc Ordinary Shares RLAY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $19.08
- Day Range
- $18.41–19.73
- 52-Week Range
- $3.03–20.79
- Bid/Ask
- $19.36 / $19.65
- Shares Outstanding
- 217.94M
- Market Cap
- $4.25B
- Volume/Avg
- 12,600 / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 318.39
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 192
- Website
- https://www.relaytx.com
Valuation
|
Metric
|
RLAY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.75 |
Price/Sales | 318.39 |
Price/Cash Flow | — |
Price/Earnings
RLAY
Financial Strength
|
Metric
|
RLAY
|
|---|---|
Quick Ratio | 21.58 |
Current Ratio | 22.13 |
Interest Coverage | — |
Quick Ratio
RLAY
Profitability
|
Metric
|
RLAY
|
|---|---|
Return on Assets (Normalized) | −31.13% |
Return on Equity (Normalized) | −34.19% |
Return on Invested Capital (Normalized) | −36.02% |
Return on Assets
RLAY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?m><qP | LOCK|%!Zg | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@M^^Bms | LOCK|gy#^n | $70B | |||
| argenx SE ADR
ARGX
| LOCK|>b#?Sz | LOCK|vBq | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$g@!>>$ | LOCK|&q>H# | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@?hHxpz | LOCK|G?y | $37B | |||
| Moderna Inc
MRNA
| LOCK|c><hk@ | LOCK|HW | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&#H&p$m | LOCK|@Qmm | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|&F&#H! | LOCK|^vm | $23B | |||
| Incyte Corp
INCY
| LOCK|<gT?%Y | LOCK|>C | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|^gq%dC | LOCK|$k> | $16B |
United States